Inhibition of SIV replication by soluble antiviral factors from sequential PBMCs of PMPA-treated/infused monkeys and control monkeys
. | 0 wk after infection . | 8 wk after infection . | 22 wk after infection . | 42 wk after infection . |
---|---|---|---|---|
. | ||||
Pre SIV p27 (% inhibition) | Pre PMPA p27 (% inhibition) | 1 wk after infusion p27 (% inhibition) | 23 wk after infusion p27 (% inhibition) | |
Targets alone | 144.6 | |||
RM1a | 123.4 (14.7) | 44.3 (69.4) | 75.8 (47.6) | 90.9 (37.1) |
RM1b | 127.9 (11.5) | 33.9 (76.6) | 81.2 (43.8) | 102.3 (29.3) |
RM3a | 118.6 (18.0) | 51.4 (64.5) | 0.9 (99.4)† | 12.7 (91.2)† |
RM3b | 126.0 (12.9) | 42.9 (70.3) | 1.1 (99.2)† | 3.2 (97.8)† |
RM3c | 132.2 (8.6) | 47.6 (67.1) | 24.4 (83.1)† | 78.8 (45.5) |
RM4a | 125.4 (13.3) | 36.9 (74.5) | 32.2 (77.7) | 31.1 (78.5) |
RM4b | 116.5 (19.4) | 38.9 (73.1) | 47.5 (67.2) | 45.5 (68.5) |
RM4c | 132.3 (8.5) | 41.1 (71.6) | 38.8 (73.2) | 32.8 (77.3) |
. | 0 wk after infection . | 8 wk after infection . | 22 wk after infection . | 42 wk after infection . |
---|---|---|---|---|
. | ||||
Pre SIV p27 (% inhibition) | Pre PMPA p27 (% inhibition) | 1 wk after infusion p27 (% inhibition) | 23 wk after infusion p27 (% inhibition) | |
Targets alone | 144.6 | |||
RM1a | 123.4 (14.7) | 44.3 (69.4) | 75.8 (47.6) | 90.9 (37.1) |
RM1b | 127.9 (11.5) | 33.9 (76.6) | 81.2 (43.8) | 102.3 (29.3) |
RM3a | 118.6 (18.0) | 51.4 (64.5) | 0.9 (99.4)† | 12.7 (91.2)† |
RM3b | 126.0 (12.9) | 42.9 (70.3) | 1.1 (99.2)† | 3.2 (97.8)† |
RM3c | 132.2 (8.6) | 47.6 (67.1) | 24.4 (83.1)† | 78.8 (45.5) |
RM4a | 125.4 (13.3) | 36.9 (74.5) | 32.2 (77.7) | 31.1 (78.5) |
RM4b | 116.5 (19.4) | 38.9 (73.1) | 47.5 (67.2) | 45.5 (68.5) |
RM4c | 132.3 (8.5) | 41.1 (71.6) | 38.8 (73.2) | 32.8 (77.3) |
SIV indicates simian immunodeficiency virus; PBMCs, peripheral blood mononuclear cells; and PMPA, 9-R-(2-phosphonylmethoxypropyl) adenine.
p27 values expressed in ng/mL of supernatant fluid (% inhibition from cultures with targets only).
P < .04.